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Abstract
Background. Hepatic injury secondary to warm ischemia and reperfusion (I/R) remains an important clinical issue following
liver surgery. The aim of this prospective, randomized study was to determine whether steroid administration may reduce
liver injury and improve short-term outcome. Patients and methods. Forty-three patients undergoing liver resection
were randomized to a steroid group or a control group. Patients in the steroid group received 500 mg of methylpredniso-
lone preoperatively. Serum levels of alanine aminotransferase (ALT), aspartate amminotransferase (AST), total bilirubin,
anti-thrombin III (AT-III), prothrombin time (PT), interleukin-6 (IL-6), and tumor necrosis factor alpha (TNF-a)
were compared between the two groups. Length of stay and type and number of complications were recorded.
Results. Postoperative serum levels of ALT, AST, total bilirubin, and inflammatory cytokines were significantly lower in the
steroid group than in controls. The postoperative level of AT-III in the control group was significantly lower than in the steroid
group (ANOVA pB0.01). The incidence of postoperative complications in the control group tended to be significantly higher
than that in the steroid group. Conclusion. These results suggest that steroid pretreatment represents a potentially important
biologic modifier of I/R injury and may contribute to maintenance of coagulant/anticoagulant homeostasis.
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Introduction
Blood loss and transfusions during liver resection are
associated with unfavorable short- and long-term
outcomes [14]. Inflow occlusion through clamping
of the portal triad (Pringle maneuver) is routinely
used in many centers to prevent blood loss during
transection of the liver parenchyma. However, the
Pringle maneuver causes ischemia and reperfusion
(I/R) injury to the remaining liver, with a risk of poor
postoperative outcome [2,5]. Diseased liver with
chronic liver disease poorly tolerates reperfusion
injury and can develop liver failure even after short
periods of ischemia [6].
Different strategies have been reported to confer a
state of protection against hepatic I/R injury [7]. In this
context, pharmacologic protection, such as the admin-
istration of steroid before or during portal clamping,
has been used to reduce I/R-dependent liver injury
and surgical stress following hepatic resection [8,9].
Although several studies in rodent models have demon-
strated the biological efficacy of steroids in attenuating
hepatic I/R injury [1014], data about the clinical
effectiveness of perioperative steroid administration in
liver surgery are still limited [1517]. The aim of this
prospective randomized study was to investigate the
effects of preoperative steroid administration on hepa-
tic ischemic injury and short-term outcome in patients
undergoing hepatic resection.
Patients and methods
Patients
From April to September 2004, 43 consecutive
patients undergoing elective hepatic resection in the
(Accepted 14 January 2007)
ISSN 1365-182X print/ISSN 1477-2574 online # 2007 Taylor & Francis
DOI: 10.1080/13651820701216984
Presented to the Annual Meeting of the American Hepato-Pancreato-Biliary Association (AHPBA), Fort Lauderdale, FL, USA, April 14 17, 2005 (Session:
Young Investigator Award).
Correspondence: Carlo Pulitano`, Department of Surgery  Liver Unit, San Raffaele Scientific Institute, Via Olgettina 60, 20132 Milano, Italy. Tel: 39 02
2643 7808. Fax: 39 02 2643 7807. E-mail: pulitano.carlo@hsr.it
HPB, 2007; 9: 183189
Department of Surgery  Liver Unit at San Raffaele
Scientific Institute, were enrolled into the trial.
Patients were assigned randomly to a steroid group
(n21) or a control group (n22). Patients in the
steroid group received 500 mg of methylprednisolone
(Pharmacia Corp., Peapack, NJ, USA) just before the
surgery. Patients requiring concomitant thoracic or
colorectal surgery, additional ablation therapies
(radiofrequency), as well as liver resections performed
under total vascular exclusion were excluded from
the study. Patients undergoing a total ischemia time of
B20 min were also excluded. All patients gave
informed consent before enrolment in the trial. Post-
operative complications were evaluated for 30 days
after surgery.
Surgical procedure
Laparatomy was performed through a right subcostal
incision and a midline incision. The intermittent
Pringle maneuver was applied at the time of liver
transection and consisted of cross-clamping of the
hepatoduodenal ligament for 20 min and releasing
the clamp for 10 min until the transection was
completed. The procedure was repeated as necessary.
Transection of the hepatic parenchyma was carried
out by a combination of the clamp fracture techni-
que, ultrasonic dissector (Soring, Quickborn, Ger-
many), and harmonic scalpel (Ultracision, Ethicon,
Cincinnati, OH, USA) along with hemostasis of the
vessels by clips or ligation, and coagulation by
electrocautery or argon beam. A closed suction drain
was placed in the peritoneal cavity in all patients.
Each patient was operated under the supervision of
the same hepatobiliary surgeon (L.A.), who was
unaware of the patient’s group allocation. Unless
clinically contraindicated, a systemic antibiotic, first-
generation cephalosporin (Cefazolin, Mead Johnson,
Princeton, NJ, USA) was routinely applied just
before the surgery, ending on the fourth postopera-
tive day.
Clinical variables
Postoperative markers of hepatocyte damage and
recovery, including alanine aminotransferase (ALT),
aspartate aminotransferase (AST), bilirubin, and
coagulative parameters [prothrombin time (PT-INR)
and antithrombin III (AT-III)] were measured on
postoperative day (POD) 1, 2, and 5. Data regarding
preoperative variables, duration of surgery, intrao-
perative blood loss and transfusion, intraoperative and
postoperative complications, and hospital stay were
collected prospectively. Underlying liver disorders
such as steatosis, fibrosis, and other types of injury
were also evaluated.
Serum levels of TNF-a and IL-6
Serum levels of TNF-a and IL-6 were measured at
the induction of anesthesia, and on POD 1, 2, and 5.
Serum levels were quantified by using an ELISA kit
according to the manufacturer’s specifications (Bouty,
Milan, Italy). Data were then presented as picograms
per milliliter of serum TNF-a. The detection limit
of the assay was 1 pg/ml for TNF-a and 0.1 pg/ml
for IL-6.
Statistical analysis
A minimal sample size of 17 patients per group was
calculated to detect a 100 U/L difference in the peak
ALT levels with a SD of 100 U/L with a level of
statistical significance of 0.05 and a power of 0.80,
using a post hoc two-sample t test. Continuous
variables were expressed using the MannWhitney
test and categorical variables were compared using the
x2 test or Fisher’s exact test, as appropriate. Multiple
comparisons were made using repeated-measure ana-
lysis of variance (ANOVA) as needed. Results are
reported as mean9SD. Significance was defined as
pB0.05. All analyses were performed using the
statistical package SPSS 12.0 (SPSS, Chicago, IL,
USA).
Results
Clinical variables of patients
Twenty-nine males and 14 females were included in
the study. There was no significant difference regard-
ing the patients’ age, gender, ischemia time, or
underlying liver disease between patients randomized
in the steroid group versus control group (Table I).
Even though ischemia time was longer in the steroid
group (48918 min) than in the control group (299
17 min), possibly because of a higher number of
extended right hepatectomies in the steroid group,
no significant difference was recorded. Thirteen
patients were operated for liver metastases from
colorectal cancer, 16 for hepatocellular carcinoma, 5
for various kinds of metastatic diseases, 3 for cholan-
giocellular carcinoma, 2 for hemangioendothelioma,
and 1 patient for gallbladder cancer. In three patients
liver resection was performed for benign diseases,
such as focal nodular hyperplasia, hemangioma or
hepatolithiasis. The different diagnoses were distrib-
uted homogeneously between the steroid and control
groups. An extended right hepatectomy was per-
formed in five patients and a formal left or right
hepatectomy was performed in nine and eight pa-
tients, respectively. Nine patients received a segmental
resection involving at least two segments, a segmen-
tectomy was performed in seven patients and a wedge
resection in five patients. The type and number of
procedures were comparable between both groups.
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Postoperative liver injury
The degree of I/R injury of the liver was assessed by
postoperative peak serum ALT and AST levels. The
transaminase peak occurred within the first post-
operative day in all patients. Patients treated with
preoperative steroid pulse had a significantly lower
peak ALT value when compared with the control
group on POD1 (3539221 vs 7529345 U/L,
p0.002) and POD2 (2959120 vs 4769280 U/L,
p0.045). Similarly, peak AST values were signifi-
cantly reduced in the steroid group when compared
with patients receiving portal clamping alone on
POD1 (3519269 vs 7939369 U/L, p0.001)
and POD2 (2319180 vs 4369210 U/L, p0.040)
(Figure 1).
The postoperative bilirubin values were also sig-
nificantly lower in the steroid group than in the
control group on POD1 (1.1690.54 vs 2.391.4
mg/dl, p0.0001), POD2 (1.1290.6 vs 1.891.1
mg/dl, p0.004), and POD5 (0.890.3 vs 1.391.0
mg/dl, p0.037) (Figure 2).
Coagulation parameters
Significant differences between the steroid and con-
trol groups were also observed for coagulant para-
meters. Prothrombin time was significantly prolonged
in the control group compared with the steroid
group on POD1 (1.2890.19 vs 1.1490.85 INR,
p0.06), POD2 (1.290.14 vs 1.1190.07 INR,
p0.023).
AT-III levels in both groups significantly decreased
compared with the preoperative levels and reached
their minimal levels on POD1. The AT-III levels in
the control group were significantly lower than in
the steroid group on POD1 (55910 vs 68913%,
p0.012), POD2 (58910.6 vs 76914%, p0.01),
and POD5 (59911 vs 83919%, p0.02) (Figure 3).
ANOVA with repeated measures revealed that the
AT-III levels in the steroid group were significan-
tly maintained compared with the control group
(pB0.01).
Serum cytokines levels
Il-6 serum levels in both groups reached a peak on
POD1 and declined thereafter, TNF-a levels peaked
later on POD2 and declined thereafter. IL-6 and
TNF-a levels in the steroid group were significantly
lower than in the control group at each time point
measured after the surgery (Table II, Figure 4).
Table I. Comparison of preoperative and intraoperative variables between the control and steroid group.
Preoperative and intraoperative variables Control group (n22) Steroid group (n21) p value
Age (years) 6598.9 60.7913.4 0.149
Gender (male/female) 16/6 13/8 0.449
Diagnosis (HCC/CCC/CMET/NCM/GBL/HEM/BEN) 10/1/6/3/1/2/1 6/2/7/2/0/0/2 0.358
Underlying liver disease (normal/hepatitis/steatosis) 11/8/3 12/7/2 0.386
Concomitant diseases
Diabetes 8 5
Hypertension 3 3
Previous systemic chemotherapy 3 3
Previous intrahepatic chemotherapy 1 1
Arrhythmia 0 2
TACE 1 2
COPD 0 2
Total [no. (%)] 16 (72%) 18 (85%) 0.295
Albumin (g/L) 4898.1 4497.2 0.132
Total bilirubin (mg/dl) 0.9290.4 0.9790.6 0.756
ALT (U/L) 37921 38921 0.896
AST (U/L) 48932 37922 0.270
Prothrombin time (INR) 1.0290.04 1.0290.05 0.926
AT-III (%) 84.5915.3 83.6916 0.894
Operative procedures (Rhr/Lhr/ExRhr/Biseg/Seg/Wedge) 6/3/1/6/3/3 2/6/4/3/4/2 0.146
Operation time (min) 4219112 378997 0.191
Ischemia time (min) 29917 48918 0.134
Blood loss (ml) 5859436 4879245 0.125
Transfusion (units)
Red blood cells 1.190.8 0.890.9 0.321
Fresh frozen plasma 1.193.2 0.792.4 0.112
HCC, hepatocellular carcinoma; CCC, cholangiocellular carcinoma; CMET, colorectal metastasis; NCM, non-colorectal metastasis; GBL,
gallbladder cancer; BEN, benign diseases; HEM, hemangioendothelioma; TACE, transarterial chemoembolization; COPD, chronic
obstructive pulmonary disease; Rhr, right hepatectomy; Lhr, left hepatectomy; ExRhr, extended right hepatectomy; Biseg, bisegmentect-
omy; Seg, segmentectomy; Wedge, wedge resection. Data are given as mean9SD.
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Postoperative complications and hospital stay
Two patients (9.5%) in the steroid group and eight
patients (37%) in the control group had one or more
complications within 30 days after surgery. The post-
operative complications are summarized in Table III.
Significantly fewer patients in the steroid group had
infectious complications, defined as positive culture of
blood, sputum, or other fluids in the presence of
clinical evidence of infection (p0.027) [18]. There
was no death within 30 days of surgery in either
group. Patients in the steroid group experienced a
reduced hospital stay compared with the control
group (p0.040).
Discussion
Hepatic injury and failure secondary to warm I/R
injury remains an important clinical issue [19]. It
occurs in a variety of situations including transplanta-
tion, trauma, shock, and liver surgery, when hepatic
inflow occlusion (Pringle maneuver) or inflow and
outflow occlusion (total vascular exclusion) are in-
duced to minimize blood loss while dividing the liver
parenchyma [20]. Therefore, there is a considerable
interest in the prevention of hepatic I/R injury.
The first reports on the protective effects of steroids
on liver ischemia were published in 1975 [12].
Santiago-Delpin and Figueroa found that methyl-
prednisolone treatment before hepatic occlusion re-
sulted in increased animal survival and reduced liver
damage, as demonstrated by histology, when com-
pared with ischemic controls. Even though the exact
molecular-biologic mechanisms of steroid action on
hepatic I/R injury remain partially unknown, it is
supposed that steroid therapy suppresses liver injury
by a variety of mechanisms, including increased tissue
blood flow and suppression of oxygen free radicals,
lysosomal proteases, suppression of calpain m activa-
tion, reduced cytokine production and apoptotic
activity [1014].
Figure 1. Comparison of mean ALT and AST levels between the control and steroid groups.
Figure 2. Comparison of mean postoperative total bilirubin levels
between the control and steroid groups.
Figure 3. Comparison of mean AT-III levels between the control
and steroid groups.
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Based on their biological effects, routine periopera-
tive administration of steroids has been advocated
to reduce hepatic ischemic injury. Although, some
series recommended the preoperative administration
of steroids [8,9], the use of corticosteroids in hepatic
surgery remains controversial and clinical benefits
are still uncertain [1517]. This disagreement prob-
ably stems from the limited number of patients, their
dosage, administration schedule, and endpoints of
clinical outcome in different studies. This prospective
randomized study in an unselected group of patients
establishes preoperative methylprednisolone adminis-
tration as a protective strategy against I/R injury in
humans. Postoperative indicators of hepatocyte da-
mage and recovery (aminotransferase, bilirubin) were
significantly modified by steroid administration.
Several clinical trials in patients undergoing elective
cardiothoracic or gastrointestinal surgery, as well as in
cases of septic shock [21], have evaluated the efficacy
of steroid administration. Results suggest that several
aspects of the surgical stress responses, organ dys-
function, and postoperative recovery are improved by
administering preoperative steroids.
The potential side effects of perioperative steroid
administration have been of much concern. However,
a meta-analysis with data from more than 1900
patients concluded that perioperative methylpredni-
solone administration in major surgery, trauma, and
spinal cord injury was not associated with any adverse
effects [22].
The liver plays an important role in maintaining
the balance between thrombosis and bleeding. Major
liver surgery is often characterized by modifications in
hemostatic balance [23,24]. Postoperative liver dys-
function following removal of significant hepatic
volume, vascular clamping, and heavy hemorrhage
may result in a hypocoagulable state. On the other
hand, a hypercoagulable status can result from
impaired synthesis of anticoagulants, hemodilution,
and excessive activation of inflammatory response
[24]. AT-III is known to play a fundamental role
in the anticoagulant system by preventing thrombin
formation and inhibiting coagulation by down-
regulating procoagulant activities [25]. Decrease of
AT-III after major surgery is associated with an
increased risk of complications and mortality
[26,27]. In addition to the anticoagulant effects, AT-
III has important anti-inflammatory activity [28].
Harada et al. have recently demonstrated that AT-III
reduces I/R induced liver injury in rats by increasing
the COX-1-mediated production of PGI1 and PGE2
[29]. Shimada et al. reported that preoperative
administration of AT-III concentrates significantly
decreases postoperative complications such as liver
failure and hyperbilirubinemia after hepatic resection
for hepatocellular carcinoma [30]. Methylpredniso-
lone administration resulted in a better preservation of
coagulative function as shown by the preserved
prothrombin time and attenuated the reduction of
AT-III. As described previously [31], methylpredni-
solone pretreatment attenuates the decrease in AT-III
by reducing the postoperative production of the
inflammatory cytokine IL-6 which occurred after
hepatic resection. Similar results were previously
Table II. Serum cytokine levels.
Cytokines
Control group
(n22)
Steroid group
(n21) p value
IL-6 preoperative 190.5 190.4 0.810
IL-6 POD1 61916.4 23918.9 0.001
IL-6 POD2 42.3913 17911 0.025
IL-6 POD5 30.296.8 11.398.6 0.012
TNF-a preoperative 0.890.4 0.790.3 0.840
TNF-a POD1 11.498.8 5.497.2 0.040
TNF-a POD2 24.7912 7.798.2 0.005
TNF-a POD5 12.996 5.394.1 0.006
Data are given as mean9SD. POD, postoperative day.
Figure 4. Comparison of mean IL-6 and TNF-a levels between the control and steroid groups.
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described for esophagectomy [32]. IL-6 certainly
has a significant role in the activation of the coagula-
tion cascade: in fact this cytokine is thought to act
over hemostasis activating the extrinsic pathway
through tissue factor expression [33]. It is of clinical
interest that preoperative steroid administration
before hepatic resection may maintain coagulant/
anticoagulant homeostasis, attenuating postoperative
cytokine levels.
Elevated plasma levels of IL-6 have been reported
to correlate with postoperative morbidity and mortal-
ity [34], and the cytokine TNF-a  one of the main
mediators of hepatic I/R injury  is known to have
both local deleterious effects on the hepatocytes and
to mediate remote organ damage [35]. Inflammatory
cytokines such as IL-6 and TNF-a are also known to
play a critical role in liver generation [36,37], and on
the other hand, hyperstimulation of IL-6 has been
suggested to inhibit liver regeneration [38]. Serum
levels of inflammatory cytokines IL-6 and TNF-a
were significantly reduced in the steroid group. This
trial confirmed the effect of suppression of surgical
stress by preoperative steroid administration in pa-
tients undergoing hepatic resection.
Infectious complications were less frequent in the
steroid group than in the control group (31% vs
4.7%). It is of great interest that the possible clinical
effects of preoperative steroid administration include
the prevention of bacterial translocation and immu-
nosuppression induced by hepatic resection itself.
Yamashita et al. [16] have previously reported that
the administration of steroids in hepatic resection
results in decreased values of immunosuppressive acid
protein, and postoperative positive rate of serum
Candida antigen, which is a marker of bacterial
translocation [39]. Similar findings were reported in
other operations, including esophagectomy [40]. In
addition, the hospital stay was significantly shorter
in the steroid group and adverse effects of steroid use,
such as abnormality in glucose tolerance and delay in
wound healing, did not occur in any of our patients.
The steroid administration regimen used in this
study was based on the following considerations. The
anti-inflammatory actions of methylprednisolone are
five times as strong as those of cortisol, but it has a
reduced activity on electrolytes [41]. The duration of
methylprednisolone’s biologic action is 36 h and the
half-life in the blood is 2.8 h [42]. As a result, both
early and late phase of hepatic I/R injury should be
covered [43]. Intravenous administration of 500 mg
of methylprednisolone has been confirmed to result
in a methylprednisolone level of1 mg/ml in blood
or10 mg/ml in liver tissue [16], and10 mg/ml of
methylprednisolone can significantly suppress lym-
phocyte blastoid transformation, immunoglobulin
production, and NK cell activity [42]. This prospec-
tive randomized study suggests that preoperative
methylprednisolone administration may represent a
valid protective strategy against hepatic ischemia
reperfusion and confirmed the efficacy and safety of
steroids in reducing surgical stress in patients under-
going hepatic resection.
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